Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Shares Traded Last Trade
  0.10 1.5% 6.75 3,106,567 11:00:26
Bid Price Offer Price High Price Low Price Open Price
6.70 6.80 6.80 6.75 6.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.05 -1.12 -0.03 227
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:43 O 120,000 6.725 GBX

Sareum (SAR) Latest News

More Sareum News
Sareum Investors    Sareum Takeover Rumours

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
25/9/202115:30Sareum 2015 8,686
05/8/202108:49No more rns until current project closed-
04/7/202120:52SAR 2013 , SHORT THE ARSE OUT OF IT THREAD326
08/1/202118:09SAR - Sareum Holdings drug discovery370
12/10/202012:29Positive Leukaemia Model19

Add a New Thread

Sareum (SAR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

Sareum Daily Update: Sareum Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 6.65p.
Sareum Holdings Plc has a 4 week average price of 6.15p and a 12 week average price of 5.75p.
The 1 year high share price is 9.75p while the 1 year low share price is currently 0.71p.
There are currently 3,365,701,148 shares in issue and the average daily traded volume is 4,695,501 shares. The market capitalisation of Sareum Holdings Plc is £227,184,827.49.
c31161: Fragi whether it goes down to 5p or not is not really the point, because a share price doesn't stay at the same price forever, its the length of time its stays at that level and the lower it goes the less effect news has on the share price lets hope news comes soon.
syndicated: There are four scenarios on the covid front - 1: agile route gets announced (delay due to red tape) 2: covid route becomes a dead end as agile access is rejected and this is shelved 3: covid route gets funded internally through current cash at bank and we go alone 4: covid route gets taken on by a partner to progress (this could mean the delay is due to partner talks, remember we may be offered agile route but a partner may want this on their portfolio) I think option 2 is least likely but would decimate the current share price I think 1 or 4 would give us a huge lift Option 3 will help “steady the boat” in terms of stabilising the share price and give possibly a 60-70% lift in price
c31161: BARKBOO: you never answered my question. All you need to do is look at my posting history. See I will tell you what happened with this stock, I was monitoring a particular stock over a period of a few days, but for some reason SAR kept catching my eye as it was rising, so I started reading I little about it, I am not an expert by any means, so a thought I would take a £20k punt, because I am a gambler and addicted to the stock market like many others and thought there's a good chance to make a few quid that day, however within and hour or so of my purchase the share price started to pull back. Now since I am in here I have done some research and believe this could be a block buster, but I am also aware that Pharmaceuticals are high risk high reward. At the moment the jury seems to be out with the traders, I don't mean out because they are not sure whether it will be successful or not, I mean it is out because they are not sure when news will come and how good or bad the news will be (all in the short term), so traders move on to something else in the mean time, LTH underpin a share price level, but traders are the ones who make the difference in spikes and drops, imo, many of you have done remarkably well not selling when the time get rough, only time will tell where this will end up but for now I think I will let my small holding ride until the end.
norma_stitts: RNS; Thu, 19th Aug 2021 07:00 RNS Number : 0737J Sareum Holdings PLC 19 August 2021 Sareum Holdings PLC ("Sareum" or the "Company") Trading Statement Cambridge, UK, 19 August 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, provides the following trading update ahead of its full year results for the year ended 30 June 2021. Sareum expects to report its full audited annual results in October 2021. OPERATIONAL HIGHLIGHTS SDC-1801 for treating symptoms of Covid-19 As noted in the Company's RNS announcement of 1 July 2021, the UKRI-funded Covid-19 research project for SDC-1801, a novel, TYK2/JAK1 inhibitor, was completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor. The in-vivo studies that have now been completed support the initial cellular results and provide strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner. The studies also showed that viral loads did not increase after SDC-1801 administration, which is a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field. SDC-1801 (autoimmune diseases) Recent delays in compound supply mean that SDC-1801 is now scheduled to commence its final preclinical studies at the beginning of Q4 2021 but the Company still aims to file a Clinical Trial Application (CTA) by the end of Q4, subject to no further delays. First clinical trials - safety studies in healthy volunteers - may commence in early 2022, subject to gaining the requisite approval and funding. SDC-1802 (cancer immunotherapy) Sareum continues to work on the design of the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. The Company announced, on 30 July 2021, that a notice of allowance had been received from the US Patent and Trademark Office in respect of a patent (Application no. 16/343,639) protecting SDC-1802 and its use in treating certain cancers. Subject to certain formalities being completed, the patent is expected to be granted within three months. Licensed Programme - SRA737: A Selective Chk1 inhibitor The Company continues to monitor licence holder Sierra Oncology's activities as it explores options to fund the future development of SRA737. Sareum continues to believe that the amended licensing agreement between Sierra and CRT Pioneer Fund (CPF) could expedite the advancement of the SRA737 programme in a timely manner. Post period-end, during an Investor Presentation on 6 August 2021, Sierra announced the in-licencing of the BET inhibitor, AZD5153, from AstraZeneca and noted potential combinations with SRA737 as a possible pipeline expansion opportunity. Financial highlights (subject to audit) · Raised £2.37m before expenses in June 2021 through two subscriptions to a high net worth individual. · Loss on ordinary activities (after taxation) for the year ended 30 June 2021 is expected to be approx. £1.6m (2020: loss of £0.96m), reflecting the increased R&D expenditure required for preclinical development. · Cash at bank as at 30 June 2021 expected to be approx. £2.7m (£1.3m as at 31 December 2020; £1.8m as at 30 June 2020). · Post period-end, in July and August 2021, raised a further £2.18m (before expenses) through a share subscriptions to two additional high net worth individuals plus an exercise of warrants. Salary Deferral Scheme The salary deferral scheme, as announced by the Company on 17 December 2019 and updated on 1 July 2020, will end in August 2021, with a total of £155k, representing all amounts outstanding, being settled in cash, following the significant c.£4.5m improvement in the Company's financial position arising from the recent share subscriptions and warrant exercise. Dr Tim Mitchell, CEO of Sareum, commented: "The past year has seen Sareum advance the preclinical development of our proprietary dual TYK2/JAK1 inhibitor programmes, with the goal of completing preclinical development of SDC-1801 and filing for clinical trials approval by the end of 2021. We are particularly pleased to have raised substantial additional funding during the period, which will be deployed to advance these programmes into clinical development and build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets."
andrbea: some posts of the recent past: MrsApeslaptop 30 Jul '21 - 11:03 - 7483 I posted this on the other place. But 1802 is worth 50p to £2 on its own as its unique. Reference point for a preclinical IL-2 inhibitor that is not unique. HTTps:// The-Oracle SUPERIOR to a miracle drug01 Aug 2021 15:13 Just a thought from what Stoney posted earlier. We are SUPERIOR, NOT just better. "On 01 July, Sareum announced that the proof of concept experiments had been completed and importantly that their kinase inhibitor drug candidate SDC-1801 had reduced the levels of cytokines associated with ARDS in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was considered superior to dexamethasone. This is great news for not only the UK but for the World." Just been playing on my mind, the aspect of something superior being near enough available, yet no one paying attention during a pandemic. Something must be going on, it's far to quiet from Sareum. hxxps:// BasilAlderman RE: Sareum FOMO =10p+ today. A Great launch pad for 20p nextToday 07:33 Sareum now has a very realistic opportunity of achieving 20p soon before moving up another x1 to 40p a share. It is pretty obvious that the latest HNWI buyng £1million Sareum shares a few days ago isn't investing to make a paltry 10% gain. They will no doubt be wanting to make at least 5 - 10 million profit from their £1 million investment in Sareum. That would suggest that they have a share price of 40p - 70p in mind. i.e. a £1billion+ price tag. Interestingly, Kymab (co-founded by Sareum NED Dr Owen) was sold for a similar amount to Sanoffi earlier this year.
syndicated: Every week that passes without an agile rns, confirming we’re on the program or not, expect the share price to bounce around. Likely we’ll get a trading update separate to the Agile rns. If we don’t get on the program the share price will seriously tank! It is possible we may not get it as the pneumonia aspect of the project failed. Of course either way the 2022 cta will be the safety net. In the mean time this is day trader fodder. Ahh, and IF partner talks make any progress expect a hockey stick rise (I really doubt this will happen as partner talks with Sareum are bit of a unicorn)
silvergreyhead1: Surely Tomgreg it's entirely what the market think SAR is worth that may take them up to 9p, setting warrants at 9 p just shows the investor thinks they will get there and is prepared to accept the share price has to reach 9p before they can access the warrants. The company have to make sure they don't set that warrant share price too high as they may need that investors cash to continue. Think any warrant share price is sort of a commitment from both sides to see the company progress.
hamidmontana: On 7 January 2021, Sareum heard it had won patent approval in the US for an invention associated with its proprietary SCD-1802 kinase inhibitor programme."The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets," said chief scientific officer Dr John Reader.Small molecule drugs have been the cornerstone of modern pharmaceuticals for over a century. Aspirin, for example, is a small molecule drug. They can enter cells easily because of their size and using science whizzbottery can even be 'programmed' to perform specific functions.On 15 June 2021 SAR issued a release saying it had received nearly £1.5m for 30m shares at 4.9p per share "by the same high net worth individual who subscribed to shares to the value of £900,000 as announced by the Company on 1 June 2021".The cash will be used to progress its SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes, the company said.This white knight, whoever they are, clearly believes in the potential here. That's left a lot of smaller investors with a Fear of Missing Out jumping aboard. Since this time last year the SAR share price has more than 10 bagged. So £5,000 invested in June 2020 would be worth approximately £55,250 today.
andrbea: some more oldies (about TYK2) from old to new: Ahfam3 RE: Where are you ?12 Oct 2020 15:42 Darkhorse aka Sherger was being paid to take it down for a low entry- so has been sacked. But his proteges will come in force as this continues to re-rate- As I said the pacific chaps don't hold 62m for nothing- so plenty of news to come. As before fantastic news on the patent and my opinion now we have the patent as soon as Sar announce intention to go to clinic we will get a deal(s) for either or both Tyk2's just like they did towards the Chk1 path. The majors know the cost goes up in ph1 and they have expiring or expired patents and are in desperate need of new drugs. So newsflow is Covid grant by end of this month and then maybe a surprise from China on aurora. So hold oh tight chaps more fantastic news to come- many happy returns chaps this is our year. AndytheMKDon Posts: 10,759 Price: 2.05 No Opinion RE: VelosBio $2.75bnToday 09:34 RMM.. Great find and good observations. Eventually investors and Insti's will twig on that this is the sort of asset value Sar have with Tyk2. We are in a very hot area and are one of only a couple of company's who have a viable product. Shouldn't be long to wait now with SDC1801 and 1802 due to enter the clinic in the coming weeks / month's. 1801 in Covid / 737 / Aurora could add a nice big dollop of cream onto what will surely be a fairly substantial cake.. gl. Andy. AndytheMKDon Posts: 10,759 Price: 2.05 No Opinion Sar and Covid.Today 12:42 When challenged as to when and if vaccines would be available even the goverments chief scientific officer fessed up yesterday on TV to say it's not all about vaccines and that a three pronged attack would include therapeutics and extensive testing. So finally even the government are waking up and understanding the important role that products like Tyk2 Jak1 will play as part of the long term solution to Covid. As we all know SDC1801 / 02 are about a lot more than just Covid. You wouldn't want to be out of this over the weekend... lol.. gla. Andy Num4 Posts: 1,708 Price: 1.55 No Opinion TYK2 and IFNAR2Today 12:07 As John mentions in the Q&A, IFNAR2 is via TYK2 and JAK1 pathway, but it is down regulated in COVID, so inhibiting IFNAR2 is worse for the patient at the start of the disease as IFNAR2 is needed to fight the initial infection, if you wipe that out then more chance of it progressing. With COVID we will need to administer a tyk2/jak1 inhibitor at the right stage of the disease, having enough benefit so that we inhibit TYK2 so the cytokine storm doesn't kill the patient but IFNAR2 inhibition is irrelevant as the disease is progressed past initial stages. As for the competition (BMS and Nimbus) having pure TYK2, then my thoughts are they have the same problem as IFNAR2 is tyk2 and Jak1 signalling. The lead researcher in the Nature paper, is looking for treatments for years to come for COVID in ICU, after that paper you can bet your bottom dollar that a TYK2 inhibitor will be administered in ICU COVID patients within the year. Pfizer should be pushing ahead with theirs and positive feedback from that will enable SDC1801 to advance quicker. There should be a queue to partner with Sareum on this, potential is huge and IMO very likely, they will want to try every TYK2 they can get their hands on, we are within a very select group of companies. RE: SRRAToday 14:39 Fingers crossed. If it is for sra737 p2 trial (looks right amount). They may release p2a data next week. We get our milestone and should consildate around 7.6p pending tyk news in summer. Fingers crossed thats what it is for. Good luck all Brighty1 Posts: 995 Price: 5.55 No Opinion RE: 7.1p todayToday 08:46 You could be right regarding 7.1p today. Certainly 6p+ looks more than possible given the volume. Remember everyone that: • Sareum’s worldwide patents are in place... • Sareum’s two TYK2/JAK1 programmes targeting autoimmune diseases and cancer (SDC 1801&1802) are progressing.... • Sareum’s commercial interest in SRRA 737 CHK1 has been re-negotiated / tidied up ready for a deal…SRA737 Combo trials with WEE1 (AZ), Keytruda (MSD) and Gemcitabine (Lilly) all successful • Sareum has a potential treatment for Covid-19…. "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2". Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients. Patience is all that is required. Good luck, Brighty Tjb68 Posts: 25 Price: 7.05 No Opinion ThisToday 16:36 Major development for UK and @Sareumplc - our orally-available TYK2 inhibitor is being tested against cytokine storm in COVID-19. Success will be good for the UK and the world! Tweet From Parker at Sareum Posts: 658 Price: 5.60 No Opinion RE: just in with 100,00017 Jun 2021 15:15 Netherwood - did you know we are expecting covid trial results within the next 3 or 4 weeks? and about to enter P1 trials for tyk2 in autoimmune. and worldwide patents in place for 1802, tyk2 in cancer. Oh, and SRA737, chk1 inhibitor complete tumor regression in small cell lung cancer and highly promising results in ovarian and anogenital cancers too
andrbea: Reminder: Brighty1 RE: ScaryToday 11:13 Nothing scary about Sareum. We know the share price is heading significantly higher because: • Sareum’s worldwide patents are in place... • Sareum’s two TYK2/JAK1 programmes targeting autoimmune diseases and cancer (SDC 1801&1802) are progressing.... • Sareum’s commercial interest in SRRA 737 CHK1 has been re-negotiated / tidied up ready for a deal…SRA737 Combo trials with WEE1 (AZ), Keytruda (MSD) and Gemcitabine (Lilly) all successful... • Sareum has a potential treatment for Covid-19…. "Initial results are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2". Plus in relation to Covid we know that our TYK2 works in combo with dexamethasone, recently hailed as the lifesaver for over 1 million Covid patients... * A HNWI has invested £2.3 million in the last couple of weeks... * News on many fronts due soon. Patience is all that is required. Good luck, Brighty workinginpharma
Sareum share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210925 16:28:17